Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Shang-Gin Wu; Chao-Chi Ho; James Chih-Hsin Yang; Shu-Han Yu; Yen-Feng Lin; Shu-Chin Lin; Bin-Chi Liao; Ching-Yao Yang; Yen-Ting Lin; Chong-Jen Yu; Ya-Ting Chuang; Wei-Yu Liao; Kah Yi Yap; Weng Si Kou; Jin-Yuan Shih

doi:10.1002/ctm2.70149

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70149 DOI: 10.1002/ctm2.70149

RESEARCH ARTICLE

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Author information +

¹. Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan

². Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

³. Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan

⁴. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

⁵. Graduate Institute of Oncology, Cancer Research Center, National Taiwan University, Taipei, Taiwan

⁶. Institute of Biotechnology, National Taiwan University, Taipei, Taiwan

⁷. Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan

⁸. Department of Public Health & Medical Humanities, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

⁹. Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

¹⁰. Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

¹¹. Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan

jyshih@ntu.edu.tw

Show less

History +

PDF

Abstract

	•The combination regimen yielded promising efficacy in NSCLC patients after EGFR-TKI resistance, particularly those with PD-L1-positive tumours.
	•Higher peritumour NK cell and lower peripheral helper T cell were associated with favourable ORR and longer PFS, respectively.
	•After disease progression, the proportion of S100A9⁺ MDSC increased, but Treg cells decreased.

Keywords

anti-angiogenesis / atezolizumab / EGFR TKI resistance / immune cell / tumour microenvironment

Cite this article

Download citation ▾

Shang-Gin Wu,Chao-Chi Ho,James Chih-Hsin Yang,Shu-Han Yu,Yen-Feng Lin,Shu-Chin Lin,Bin-Chi Liao,Ching-Yao Yang,Yen-Ting Lin,Chong-Jen Yu,Ya-Ting Chuang,Wei-Yu Liao,Kah Yi Yap,Weng Si Kou,Jin-Yuan Shih. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clinical and Translational Medicine, 2025, 15(1): e70149 DOI:10.1002/ctm2.70149

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.